Media Summary: During the Multiple Myeloma Hub Steering Committee Meeting in April 2025, key opinion leaders met to discuss the Learn more about Minimal Residual Disease ( Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the current and future
Mrd In Mm Implications For Clinical Practice And Trial Design - Detailed Analysis & Overview
During the Multiple Myeloma Hub Steering Committee Meeting in April 2025, key opinion leaders met to discuss the Learn more about Minimal Residual Disease ( Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the current and future Alessandro Gozzetti, MD, PhD, Azienda Ospedaliera Universitaria Senese, Siena, Italy, shares the main findings of his recent ... Sarah Holstein, MD, PhD, University of Nebraska Recorded on April 12, 2022 as part of the Minimal Residual Disease Chapter in the Myeloma Crowd Community by HealthTree ...
Sagar Lonial, MD, FACP, Professor and Chair, Department of Hematology and Ravi Vij & Dr. Attaya Suvannasankha, MD Discusses About Saad Usmani, MD, MBBS, MBA, of the Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC, talks on the role of ... Sham Mailankody, MBBS, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses Adaptive Symposium - COMy Online 2020 An overview of sequence-based immune receptor profiling Lanny Kirsch, USA The ... Jesús San Miguel, MD, PhD, University of Navarra, Pamplona, Spain, comments on the role of measurable residual disease ...
Watch this patient-friendly animated video that explains the most important concepts for patients on Minimal Residual Disease ... Bruno Paiva, PhD of the University of Navarra, Pamplona, Spain gives an overview of his talk on immunophenotyping for multiple ... There are currently no concrete guidelines for how to
